WO2024033533A1 - Composition d'hydratation - Google Patents

Composition d'hydratation Download PDF

Info

Publication number
WO2024033533A1
WO2024033533A1 PCT/EP2023/072316 EP2023072316W WO2024033533A1 WO 2024033533 A1 WO2024033533 A1 WO 2024033533A1 EP 2023072316 W EP2023072316 W EP 2023072316W WO 2024033533 A1 WO2024033533 A1 WO 2024033533A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydration
sodium
citrate
composition
potassium
Prior art date
Application number
PCT/EP2023/072316
Other languages
English (en)
Inventor
Sean Paul LAVIN
Alexandra Matti Helene NORRED
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Publication of WO2024033533A1 publication Critical patent/WO2024033533A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/34—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/36—Terpene glycosides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Definitions

  • the present invention is directed to a hydration composition
  • a hydration composition comprising allulose, one or more sodium salts, and one or more potassium salts, and having less than about 10%, preferably less than about 5%, more preferably less than about 3%, and most preferably less than about 1%, or 0%, by weight, of a nutritive or artificial sweetener, as well as formulations and methods of making and using the hydration composition.
  • Hydration formulas generally relate to beverages, or pre-mixes thereof, that are designed to help prevent dehydration. Dehydration can lead to severe and serious health complications including but not limited to seizures, kidney failure, and in some cases, may even be life threatening. However, being sufficiently hydrated will help avoid such serious health complications, and helps regulate body temperature, prevent infections, deliver nutrients to cells, and keeps organs functioning properly.
  • hydration formulations exploit the glucose-sodium active transport mechanism to enhance absorption of water into the bloodstream.
  • sodium passes into intestinal epithelial cells via co-transport with glucose by way of the SGLT 1 protein.
  • Two sodium ions and one molecule of glucose are transported together across the epithelial cell membrane to the bloodstream via the SGLT1 protein.
  • the absorption of glucose and sodium out of the small intestine creates an osmotic force.
  • water molecules move into the epithelial cells to maintain osmotic equilibrium. Water that is absorbed from the lumen of the small intestine rather than being excreted is available for systemic distribution by the bloodstream for cellular hydration. Water is thus delivered to the bloodstream faster and in larger quantities than by drinking water alone.
  • a hydration formula that does not contain sugar, such as glucose, for many reasons including health concerns (such as diabetes) as well as a desire to reduce sugar intake and/or have a glucose sensitivity. It is expected that consumers would also prefer a hydration formula with little or no artificial sweetener.
  • the inventors of the present application desired to create an oral hydration or replacement solution without including glucose, and without a significant amount of nutritive or artificial sugars, while still delivering faster and better hydration than water alone, as well as providing a desirable taste for consumers. Additionally, the inventors of the present application desired to create an oral hydration formula to meet the requirements of the World Health Organization (WHO) osmolality ranges 210-268 mOsm/L without including glucose, and without a significant amount of nutritive or artificial sugars, while still delivering faster and better hydration than water alone.
  • WHO World Health Organization
  • a hydration composition comprising allulose; one or more sodium salts; and one or more potassium salts; wherein the composition has less than less than about 10%, preferably less than about 5%, more preferably less than about 3%, and most preferably less than about 1%, or 0%, by weight, of a nutritive or artificial sweetener; and wherein, optionally, at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof
  • a hydration formulation comprising the hydration composition as described herein.
  • a hydration formulation comprising a hydration composition, wherein the hydration composition comprises: (a) core base, wherein the core base comprises allulose and sodium chloride; and (b) an electrolyte base, wherein the electrolyte base comprises one or more potassium salts, and one or more sodium salt excludes sodium chloride; wherein, optionally, the core base comprises at least one amino acid, and wherein, optionally, at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • a method for making the hydration composition as described herein.
  • Figure 1 presents graphs showing the effect of a hydration formula with glucose (HM) and a test solution, SF (an allulose-containing hydration formula with limited amounts of stevia and otherwise free of nutritive, non-nutritive and artificial sweeteners on transepithelial electrical resistance (TEER) (A, C, E, and G) and liquid absorption (B, D, F, and H) in Caco-2/TC7 monolayers.
  • TEER and liquid volume were measured after 1 , 3, 6, and 24 hours of treatment.
  • TEER values represent % in comparison to the values obtained before the treatments. Liquid volume are reported as mL, positive values represent passage from luminal to basolateral compartment, while negative values represent passage from basolateral to luminal compartment. Results are Mean ⁇ SD of 1 experiment, in triplicate.
  • Figure 2 shows the calculated osmolarity at the luminal and basolateral compartments, according to the treatments described below.
  • FIG. 3 Graphs showing the effect of a glucose-containing rehydration formula (HM) and allulose-containing hydration formula with limited amounts of stevia and otherwise free of nutritive, non-nutritive and artificial sweeteners (SF) on transepithelial electrical resistance (TEER) (A, C) and liquid absorption (B, D) in Caco-2/TC7 monolayers.
  • TEER values represent % in comparison to the values obtained before the treatments. Liquid volume are reported as mL, positive values represent passage from luminal to basolateral compartment, while negative values represent passage from basolateral to luminal compartment. Results are Mean ⁇ SD of 1 experiment, in triplicate.
  • FIG. 4 Graphs showing effect of treatments on cell viability (A) and relative paracellular permeability (B). Cell viability was assessed by MTT assay and it represents % in comparison to Control. Relative paracellular permeability represents the % of passage of permeability tracker LY across Caco-2/TC7 monolayers. Results are Mean ⁇ SD of 1 experiment, in triplicate, and are at 24 hours.
  • FIG. 1 Effect of treatments on cell viability (A) and relative paracellular permeability (B).
  • Cell viability was assessed by MTT assay and it represents % in comparison to Control.
  • Relative paracellular permeability represents the % of passage of permeability tracker LY across Caco-2/TC7 monolayers. Experiments were performed after 24 hours of treatment followed by 6 hours of exposure to mannitol 2.5% in the lower compartment (recovery time). Results are Mean ⁇ SD of 1 experiment, in triplicate.
  • FIG. 6 Graphs showing the effect of treatments on cell viability (A) and relative paracellular permeability (B).
  • Cell viability was assessed by MTT assay and it represents % in comparison to Control.
  • Relative paracellular permeability represents the % of passage of permeability tracker LY across Caco-2/TC7 monolayers. Experiments were performed after 48 hours of treatment followed by 6 hours of exposure to mannitol 2.5% in the lower compartment (recovery time). Results are Mean ⁇ SD of 1 experiment, in triplicate.
  • a hydration composition as used herein includes at least: allulose, one or more sodium salts and one or more potassium salts.
  • a hydration composition comprising: (a) allulose; (b) one or more sodium salts; and (c) one or more potassium salts, wherein the hydration composition has less than about 10%, preferably less than about 5%, more preferably less than about 3%, and most preferably less than about 1%, or 0%, by weight, of any of nutritive or artificial sweetener.
  • the hydration composition is in the form of a powder, gel, emulsion, or effervescent tablet, having less than about 5%, or less than about 3%, or than about 1 %, or about 0%, or about 0% to about 1 %, or about 0.005% to about 0.5%, or about 0.01% to about 0.1 % by weight water.
  • at least one amino acid is included in the hydration composition.
  • a hydration composition comprising: (a) a core base comprising allulose and sodium chloride, and optionally at least one amino acid, and (b) an electrolyte base comprising one or more potassium salts, and optionally, one or more sodium salts other than sodium chloride, wherein the hydration composition has less than about 10%, preferably less than about 5%, more preferably less than about 3%, and most preferably less than about 1 %, or 0%, by weight, of any of nutritive or artificial sweetener.
  • the “core base” and “electrolyte base” are precursors to the hydration composition.
  • the hydration composition is in the form of a powder, gel, emulsion, or effervescent tablet, having less than about 5%, or less than about 3%, or than about 1%, or about 0%, or about 0% to about 1 %, or about 0.005% to about 0.5%, or about 0.01 % to 0.1% by weight water.
  • the hydration composition includes at least one citrate salt.
  • a citrate salt refers to sodium citrates such as disodium citrate and trisodium citrate, potassium citrate, and zinc citrate.
  • at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • allulose which also refers to d-allulose, psicose, and/or d-psicose, refers to a rare sugar which has significantly less calories than sucrose.
  • the amount of allulose in the hydration composition as described herein is about 20% to about 80%, or about 20% to about 40%, or about 25% to about 35%, or about 28% to about 32%, or about 50% to about 80%, or about 50% to about 70%, or about 55% to about 70%, or about 55% to about 65%, or about 58% to about 63%, based on the total weight of the hydration composition, including any amount or ranges subsumed therein.
  • the term “nutritive or artificial sweetener” refers to glucose, fructose, galactose, sucrose, lactose, maltose, dextrose, sucralose, honey, agave, molasses, com syrup (including high fructose com syrup), xylitol, sorbitol, acesulfame potassium (Ace-K), monk fruit (Luo Han Guo), sodium saccharide, saccharin, erythritol , neotame, tagatose, aspartame, and stevia such as RebA, Reb D, RebM, and steviol glycosides.
  • a nutritive or artificial sweetener does not include allulose.
  • the hydration composition as described herein has less than about 10%, preferably less than about 5%, more preferably less than about 3%, and most preferably less than about 1%, or 0%, by weight, based on the total weight of the hydration composition, of a nutritive or artificial sweetener.
  • the hydration composition as described herein is free of any nutritive or artificial sweetener.
  • the hydration composition as described herein has about 0.01% to about 10%, or about 0.01% to about 5%, or 0.01% to about 3%, or about 0.01% to about 2%, or about 0.01 to about 1.5%, or about 0.01 to about 1.2%, or about 0.01 to about 1.1% or about 0.01 to about 1% or about 0.01 to about 0.9%, or about 0.01 to about 0.5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1 to about 1.5%, or about 0.1 to about 1.2%, or about 0.1 to about 1.1% or about 0.1 to about 1% or about 0.1 to about 0.9%, or about 0.1 to about 0.5%, based on the total weight of the hydration composition, including any amount or ranges subsumed therein.
  • the nutritive or artificial sweetener is stevia, in the absence of any other nutritive or artificial sweeteners, as defined herein.
  • the one or more sodium salts included in the hydration composition is sodium chloride, monosodium phosphate, disodium phosphate, trisodium phosphate, sodium citrates (such as disodium citrate and/or trisodium citrate), sodium carbonate, sodium bicarbonate, sodium lactate, sodium gluconate, tetrasodium acid pyrophosphate, sodium acid sulfate, sodium hydroxide, and/or mixtures or combination thereof.
  • the sodium salt is sodium chloride, sodium citrates and/or mixtures or combinations thereof.
  • the total amount of the one more sodium salts is about 5% to about 20%, or about 5% to about 15%, or about 5% to about 12%, or about 7% to about 18%, or about 7% to about 15%, or about 7% to about 12%, or about 8% to about 12%, or about 9% to about 12%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • sodium chloride may be at least one of the one or more sodium salts included the hydration composition.
  • the amount of sodium chloride is about 2% to about 10%, or about 4% to about 10%, or about 5% to about 10%, or about 6% to about 10%, or about 7% to about 10%, or about 4% to about 8%, or about 5% to about 8%, or about 6% to about 8%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • sodium citrates such as disodium citrate and trisodium citrate
  • sodium citrates may be at least one of the one or more sodium salts included in the hydration composition.
  • the amount of sodium citrates, such as disodium citrate and/or trisodium citrate is about 1% to about 10%, or about 1% to about 8%, or about 1% to about 6%, or about 1% to about 5%, or about 2% to about 8%, or about 2% to about 6%, or about 2% to about 5%, or about 3% to about 5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the weight ratio of allulose to sodium citrates in the hydration composition as described herein is about 20: 1 to about 5: 1 , or about 20: 1 to about 15: 1 , or about 18:1 to about 16: 1 , or about 10:1 to about 5:1, or about 9: 1 to about 6: 1 , or about 8: 1 to about 6:1.
  • the one or more sodium salts are sodium chloride and sodium citrates.
  • the weight ratio of sodium chloride to sodium citrates in the hydration composition as described herein is about 3:1 to about 1:3, or about 3:1 to about 1 :1 , or about 2: 1 to about 1 :2, or about 2: 1 to about 1 :1.
  • the one or more potassium salts included in the hydration composition is potassium chloride, potassium phosphate, dipotassium phosphate, potassium citrate, potassium carbonate, potassium bicarbonate, potassium hydroxide, and/or mixtures or combination thereof. In one aspect, the one or more potassium salts is dipotassium phosphate, potassium citrate, and/or mixtures or combination thereof.
  • the total amount of the one or more potassium salts is about 1% to about 20%, or about 3% to about 15%, or about 3% to about 12% or about 3% to about 10%, or about 3% to about 8%, or about 5% to about 12%, or about 5% to about 10%, or about 5% to about 8%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • potassium citrate may be at least one of the one or more potassium salts included in the hydration composition included in the hydration composition.
  • the amount of potassium citrate is about 1% to about 10%, or about 1% to about 8%, or about 3% to about 9%, or about 3% to about 7%, or about 3% to about 6%, or about 4% to about 6%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the weight ratio of allulose to potassium citrate in the hydration composition as described herein is about 20: 1 to about 5:1, or about 18:1 to about 10:1, or about 15:1 to about 10: 1 , or about 15:1 to about 12:1.
  • dipotassium phosphate may be at least one of the one or more potassium salts included in the hydration composition.
  • the amount of dipotassium phosphate is about 1% to about 10%, or about 1% to about 5%, or about 1 % to about 3%, or about 1.5% to about 3%, or about 1.5% to about 2.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the one or more potassium salts are potassium citrate and dipotassium phosphate.
  • the weight ratio of potassium citrate to dipotassium phosphate in the hydration composition as described herein is about 4:1 to about 1:4, or about 4:1 to about 2:1 , or about 4:1 to about 1 :1, or about 3:1 to about 1:3, or about 3:1 to about 1 :1.
  • the total amount of sodium salt(s) and potassium salt(s) in the hydration composition as described herein is about 5% to about 30%, or about 10% to about 30%, or about 10% to about 20%, or about 15% to about 30%, or about 15% to about 20% based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the weight ratio of allulose to total amount of sodium salt(s) and potassium salt(s) in the hydration composition as described herein is about 5:1 to about 1 :1, or about 5:1 to about 1.5:1, or about 5:1 to about 2:1 , or about 5:1 to about 3:1 , or about 4:1 to 1:1 , or about 4:1 to about 1.5:1 , or about 4:1 to about 2:1, or about 4:1 to about 3:1 , or about 2:1 to about 1:2, or about 2:1 to about 1 :1.
  • the one or more sodium salts are sodium chloride and/or sodium citrates
  • the one or more potassium salts are dipotassium phosphate and/or potassium citrate.
  • the weight ratio of allulose to total amount of citrate salts in the hydration composition as described herein is about 10:1 to 1:1 , or about 10:1 to about 5:1, or about 10:1 to about 7:1 , or about 9:1 to about 6:1, or about 9:1 to about 7:1, or about 4:1 to 1:1 , or about 4:1 to about 2:1 , or about 4:1 to about 3:1 , or about 2:1 to about 1 :2, or about 2:1 to about 1:1.
  • the citrate salts are sodium citrate and/or potassium citrate.
  • the hydration composition optionally contains calcium chloride, calcium carbonate, magnesium chloride, magnesium carbonate, or a combination thereof, in an amount of about 0.1% to about 10%, or about 0.1% to about 5%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.1 to about 1%, or about 0.5% to about 2%, or about 0.5% to about 1.5%, or about 0.5% to about 1%, or about 1% to about 10%, or about 1% to about 5%, or about 1% to about 3%, or about 1.5% to about 3%, or about 1.5% to about 2.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the hydration composition as described herein optionally contains at least one amino acid or an amino acid analogue.
  • the amino acid(s) included in the hydration composition may be sodium glutamate, potassium glutamate, L-glutamic acid monosodium hydrate, D-glutamic acid monosodium hydrate, L-glutamic acid, D-glutamic acid, D-alanine, D-glutamine, lysine, L-lysine, threonine, L-threonine, serine, L-serine, leucine, L-leucine, iso-leucine, valine, L-valine and/or any salts, combinations or mixtures thereof.
  • the hydration composition includes at least one of glutamine, L-glutamine, alanine, L-alanine, glycine, L-glycine, alanylglutamine, L-alanyl-glutamine and/or any salts, combinations, or mixtures thereof.
  • At least one amino acid is included in the hydration composition as described herein, in an amount of about 1% to about 15%, or about 5% to about 15%, or about 8% to about 15%, or about 10% to about 15%, or about 12% to about 15%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • glutamine or L-glutamine is included in the hydration composition as described herein, in an amount of about 1% to about 15%, or about 5% to about 15%, or about 8% to about 15%, or about 10% to about 15%, or about 12% to about 15%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • alanine or L-alanine is included in the hydration composition as described herein, in an amount of about 1% to about 15%, or about 5% to about 15%, or about 8% to about 15%, or about 10% to about 15%, or about 12% to about 15%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • alanylglutamine or L-alanyl-glutamine is included in the hydration composition as described herein, in an amount of about 1% to about 15%, or about 5% to about 15%, or about 8% to about 15%, or about 10% to about 15%, or about 12% to about 15%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the total amount of amino acids included in the hydration composition as described herein is about 1% to about 30%, or about 1 % to about 15%, or about 1% to about 10%, or about 5% to about 30%, or about 5% to about 15%, or about 10% to about 30%, or about 15% to about 30%, or about 20% to about 30%, or about 25% to about 30%, based on the total weight of the composition, including any amounts or ranges subsumed therein.
  • the amino acids are L-glutamine, L-alanine, alanyl-glutamine, L-alanyl-glutamine, or mixtures or combinations thereof.
  • the amino acids are L-glutamine and/or L-alanine.
  • the weight ratio of allulose to total amino acid in the hydration composition as described herein is about 3:1 to about 1 :1 , or about 2:1 to about 1 :2, or about 2:1 to about 1 :1.
  • the hydration composition as described herein may optionally include at least one processing aid.
  • a processing aid may be silicon dioxide, sodium aluminum silicate, magnesium stearate, rice hull powder, and any combination thereof.
  • the total amount of processing aids included in the hydration composition, as described herein is about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1 % to about 5%, or about 0.1% to about 3%, or about or about 0.1% to about 2%, or about or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the hydration composition as described herein may optionally contain additional agent(s).
  • Additional agents refers to, for example, vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • the total amount of additional agent(s) present in the hydration composition as disclosed herein is about 0.001% to about 30%, or about 0.01% to about 30%, about 0.1% to about 30%, or 0.001% to about 20%, or about 0.01% to about 20%, about 0.1% to about 20%, or about 0.001% to about 15%, or about 0.01% to about 15%, or about 0.01% to about 10%, or about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.01% to about 1%, about or about 0.1 to about 10%, or about 0.1 to about 5%, or about 0.1 to about 2%, or about 0.1 to about 1%, or about 0.1 to about 0.5%, based on the total weight of the composition, including any amounts or ranges subsumed therein.
  • each additional agent may be present in an amount of about 0.001% to about 15%, or about 0.01% to about 15%, or about 0.01% to about 10%, or about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.01% to about 1%, about or about 0.1 to about 10%, or about 0.1 to about 5%, or about 0.1 to about 2%, or about 0.1 to about 1%, or about 0.1 to about 0.5%, based on the total weight of the composition, including any amounts or ranges subsumed therein.
  • vitamins may optionally be included in the hydration composition, including but not limited to vitamin A, vitamin B1 , vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, and any combinations thereof.
  • the hydration composition includes vitamin B and vitamin C, preferably vitamin B3, vitamin B5, vitamin B6, vitamin B12, and vitamin C.
  • one or more mineral may optionally be included, generally salts, in the hydration composition, including but not limited to zinc, copper, manganese, nickel, tin, silicon, molybdenum, selenium, chromium, vanadium, boron, calcium, iron, iodine, phosphorus, and any combinations thereof.
  • herbal/botanical/plant supplements may optionally be included in the hydration composition, including but not limited to valerian, chamomile, passionflower, yerba mate, ginger, carrot, echinacea, mushrooms (such as reishi or cordyceps), coconut (such as coconut water and coconut water) ginseng, ashwagandha, theobromine, and any combinations thereof.
  • antioxidants may optionally be included in the hydration composition, including but not limited to carotene, eugenol, lutein, lycopene, EGCG, green tea extract, white tea, green coffee extract, and any combinations thereof.
  • a probiotic and/or a prebiotics may optionally be included in the hydration composition, including but not limited to Lactobacillus reuteri, Lactobacillus acidophilus, and Bifidobacterium bifidum, Bacillus coagulans, inulin, FOS, GOS, XOS, bacteriophages.
  • a fermented ingredients may optionally be included in the hydration composition, including but not limited to fermented ginger, fermented lemongrass, short chain fatty acids, acetic acid, lactic acid, butyric acid, and propionic acid.
  • a hormone may optionally be included in the hydration composition, including but not limited to melatonin.
  • a flavoring may optionally be included in the hydration composition.
  • Flavorings as described herein, may have about 0.01% to about 2%, or about 0.01% to about 1.5%, or about 0.01 to about 1.2%, or about 0.01 to about 1.1%, or about 0.01% to about 1%, or about 0.01% to about 0.5%, or about 0.01% to about 0.25%, or about 0.01% to about 0.1%, or 0% of a nutritive or artificial sweetener as described herein, by weight of the flavoring composition.
  • the hydration composition as described herein in the form of a powder, gel, emulsion, or effervescent tablet, having about 0% to about 1%, or about 0.005% to about 0.5%, or about 0.01% to about 0.1% by weight water, includes (a) allulose in an amount of about 50% to about 80%, or about 50% to about 70%, or about 55% to about 70%, or about 55% to about 65%, or about 58% to about 63%, based on the total weight of the hydration composition; (b) one or more sodium salts, in an amount of about 7% to about 15%, or about 7% to about 12%, or about 8% to about 12%, or about 9% to about 12%, based on the total weight of the hydration composition; and (c) one or more potassium salts, in an amount of about 3% to about 10%, or about 3% to about 8%, or about 5% to about 12%, or about 5% to about 10%, or about 5% to about 8%, based on the
  • the hydration composition has at least one citrate salt selected from sodium citrates, potassium citrate, zinc citrate, and/or any combinations or mixtures thereof.
  • at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • the amount of a nutritive or artificial sweetener is about 0.01% to about 3%, or about 0.01% to about 2%, or about 0.01% to about 1.5%, or about 0.01% to about 1.2%, or about 0.01% to about 1.1% or about 0.01% to about 1%, or 0% based on the total weight of the hydration, wherein nutritive or artificial sweetener is stevia.
  • the hydration composition further comprises a processing aid in an amount of about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1% to about 5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • At least one additional agent is included in the hydration composition selected from vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • the hydration composition as described herein in the form of a powder, gel, emulsion, or effervescent tablet, having about 0% to about 1%, or about 0.005% to about 0.5%, or about 0.01 % to about 0.1 % by weight water, includes (a) allulose in an amount of about 50% to about 80%, or about 50% to about 70%, or about 55% to about 70%, or about 55% to about 65%, or about 58% to about 63%, based on the total weight of the hydration composition; (b) one or more sodium salts, wherein the one or sodium salts is sodium chloride, sodium citrate and/or a mixture or combination thereof in an amount of about 7% to about 15%, or about 7% to about 12%, or about 8% to about 12%, or about 9% to about 12%, based on the total weight of the hydration composition; and (c) one or more potassium salts, wherein the potassium salt is potassium citrate, dipotassium phosphate or mixtures thereof in
  • the amount of a nutritive or artificial sweetener is about 0.01% to about 3%, or about 0.01% to about 2%, or about 0.01% to about 1.5%, or about 0.01% to about 1.2%, or about 0.01% to about 1.1% or about 0.01% to about 1%, or 0% based on the total weight of the hydration, wherein nutritive or artificial sweetener is stevia.
  • the hydration composition further comprises a processing aid in an amount of about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1% to about 5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • At least one additional agent is included in the hydration composition selected from vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • the hydration composition as described herein in the form of a powder, gel, emulsion, or effervescent tablet, having about 0% to about 1%, or about 0.005% to about 0.5%, or about 0.01% to about 0.1% by weight water, includes (a) allulose in an amount of about 20% to about 40%, or about 25% to about 35%, or about 28% to about 32%, based on the total weight of the hydration composition; (b) one or more sodium salts, in an amount of about 7% to about 15%, or about 7% to about 12%, or about 8% to about 12%, or about 9% to about 12%, based on the total weight of the hydration composition; (c) one or more potassium salts, in an amount of about 3% to about 10%, or about 3% to about 8%, or about 5% to about 12%, or about 5% to about 10%, or about 5% to about 8%, based on the total weight of the hydration composition.
  • the hydration composition has at least one citrate salt selected from sodium citrates, potassium citrate, zinc citrate, and/or any combinations or mixtures thereof.
  • at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • the amount of a nutritive or artificial sweetener is about 0.01% to about 3%, or about 0.01 % to about 2%, or about 0.01 % to about 1.5%, or about 0.01 % to about 1.2%, or about 0.01% to about 1.1% or about 0.01% to about 1%, or 0% based on the total weight of the hydration, wherein nutritive or artificial sweetener is stevia.
  • the hydration composition comprises at least one amino acid selected from glutamine, L-glutamine, alanine, L-alanine and/or combinations thereof, and when present, the total amount of amino acids included in the hydration composition is about 5% to about 15%, or about 10% to about 30%, or about 15% to about 30%, or about 20% to about 30%, or about 25% to about 30%, based on the total weight of the hydration composition.
  • the hydration composition further comprises a processing aid in an amount of about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1% to about 5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • At least one additional agent is included in the hydration composition selected from vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • the hydration composition as described herein in the form of a powder, gel, emulsion, or effervescent tablet, having about 0% to about 1%, or about 0.005% to about 0.5%, or about 0.01 % to about 0.1 % by weight water, includes (a) allulose in an amount of about 20% to about 40%, or about 25% to about 35%, or about 28% to about 32%, based on the total weight of the hydration composition; (b) one or more sodium salts, wherein the one or more sodium salts is sodium chloride, sodium citrate or a mixture or combination thereof in an amount of about 7% to about 15%, or about 7% to about 12%, or about 8% to about 12%, or about 9% to about 12%, based on the total weight of the hydration composition; (c) one or more potassium salts, wherein the one or more potassium salts is potassium citrate, dipotassium phosphate or mixtures thereof in an amount of about 3% to about 10%, or about 3% to
  • the amount of a nutritive or artificial sweetener is about 0.01% to about 3%, or about 0.01% to about 2%, or about 0.01% to about 1.5%, or about 0.01% to about 1.2%, or about 0.01% to about 1.1% or about 0.01% to about 1%, or 0% based on the total weight of the hydration, wherein nutritive or artificial sweetener is stevia.
  • the hydration composition comprises at least one amino acid selected from glutamine, L-glutamine, alanine, L-alanine and/or combinations thereof, and when present, the total amount of amino acids included in the hydration composition is about 5% to about 15%, or about 10% to about 30%, or about 15% to about 30%, or about 20% to about 30%, or about 25% to about 30%, based on the total weight of the hydration composition.
  • the hydration composition further comprises a processing aid in an amount of about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1% to about 5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • At least one additional agent is included in the hydration composition selected from vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • the hydration composition as described herein in the form of a powder, gel, emulsion, or effervescent tablet, having about 0% to about 1%, or about 0.005% to about 0.5%, or about 0.01 % to about 0.1 % by weight water, and includes (a) a core base comprising allulose and sodium chloride, and (b) an electrolyte base comprising one or more potassium salts, and optionally, one or more sodium salts other than sodium chloride, as described herein.
  • At least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • the core base is about 45% to about 90%, or about 50% to about 85%, or about 55% to about 80%, or about 60% to about 75%, or about 65% to about 70%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the electrolyte base is about 2% to about 20%, or about 5% to about 18%, or about 7% to about 15%, or about 8% to about 12%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • the weight ratio of the core base to the electrolyte base in the hydration composition is about 10: 1 to 1 : 1 , or about 8: 1 to 4: 1 , or about 7:1 to about 5:1.
  • the amount of a nutritive or artificial sweetener is about 0.01% to about 3%, or about 0.01% to about 2%, or about 0.01% to about 1.5%, or about 0.01% to about 1.2%, or about 0.01% to about 1.1% or about 0.01% to about 1%, or 0% based on the total weight of the hydration, wherein nutritive or artificial sweetener is stevia.
  • the hydration composition further comprises a processing aid in an amount of about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1% to about 5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • At least one additional agent is included in the hydration composition selected from vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • the hydration composition as described herein in the form of a powder, gel, emulsion, or effervescent tablet, having about 0% to about 1%, or about 0.005% to about 0.5%, or about 0.01% to about 0.1% by weight water, and includes (a) a core base comprising allulose, sodium chloride and at least one amino acid, and (b) an electrolyte base comprising one or more potassium salts, and optionally, one or more sodium salts other than sodium chloride.
  • At least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • the at least one amino acid is L-alanine and/or L- glutamine.
  • the core base is about 45% to about 90%, or about 50% to about 85%, or about 55% to about 80%, or about 60% to about 75%, or about 60% to about 70%, or about 60% to about 65%, based on the total weight of the composition, including any amounts or ranges subsumed therein.
  • the electrolyte base is about 2% to about 20%, or about 5% to about 18%, or about 7% to about 15%, or about 8% to about 15%, or about 10% to about 13%, based on the total weight of the composition, including any amounts or ranges subsumed therein.
  • the weight ratio of the core base to the electrolyte base is about 10:1 to 1 :1, or about 8:1 to 3:1 , or about 7:1 to about 4:1.
  • the amount of a nutritive or artificial sweetener is about 0.01% to about 3%, or about 0.01% to about 2%, or about 0.01% to about 1.5%, or about 0.01% to about 1.2%, or about 0.01 % to about 1.1%, or about 0.01 % to about 1 %, or 0% based on the total weight of the hydration, wherein nutritive or artificial sweetener is stevia.
  • the hydration composition further comprises a processing aid in an amount of about 0.01% to about 5%, or about 0.01% to about 2%, or about 0.1% to about 5%, or about 0.1% to about 3%, or about 0.1% to about 2%, or about 0.1% to about 1.5%, or about 0.5% to about 1.5%, based on the total weight of the hydration composition, including any amounts or ranges subsumed therein.
  • At least one additional agent is included in the hydration composition selected from vitamins, minerals, caffeine, proteins, herbal/botanical/plant supplements, nutraceuticals, enzymes, probiotics, prebiotics, postbiotics, fermented ingredients, polysaccharides, fats, phytosterols, soluble fiber, insoluble fiber, antioxidants, glucosamine, glycosaminoglycans, adaptogens, nootropics, hormones, flavoring, colorants, preservatives, anti-caking agents, gelling agents, antimicrobials, citric acid and/or other acidifiers, emulsifiers, effervescing agents, and/or excipients.
  • a hydration formulation which includes the hydration composition as described herein, which is combined with a beverage product.
  • a beverage product is suitable for consumption by drinking such as alcoholic or non-alcoholic beverages (e.g., water, carbonated beverages including carbonated water or soda, coffee, tea, wine, beer, liqueurs, spirits, beverages with fruitflavoring or juices including lemonades, nectars, fruit and vegetable juices including but not limited to pomegranate juice, beetroot juice, cranberry juice, apple juice, pineapple juice, and/or orange juice, milk including dairy milk and dairy milk alternatives including plant-based milks such as almond milk, coconut milk, oat milk, rice milk or soy milk).
  • alcoholic or non-alcoholic beverages e.g., water, carbonated beverages including carbonated water or soda, coffee, tea, wine, beer, liqueurs, spirits, beverages with fruitflavoring or juices including lemonades, nectars, fruit and vegetable juices including but not limited to pomegranate juice, beetroot
  • the beverage product is water or carbonated water.
  • the hydration composition is added to the beverage product by the consumer, such that hydration composition is mixed with the beverage product, and preferably dissolves in the beverage product creating a hydration formulation.
  • the hydration formulation is sold to the consumer (e.g., ready to drink, with the hydration composition incorporated therein).
  • the hydration composition as described herein once diluted to the desired concentration as described herein, and when the optional additional ingredients are added, has a total osmolarity that falls within at least one of the standard or "reduced osmolarity ORS" ranges recommended by UNICEF and WHO (200 to 310 mmol/L and 210 to 260 mmol/L, respectively). See WHO Drug Information Vol. 16, No. 2, 2002, "New formula oral hydration salts," available online at apps.who.int/medicinedocs/en/d/Js4950e/2.4.html.
  • Osmolarity is the concentration of a solution expressed as the total number of solute particles per liter. Osmolarity may also be expressed in units of milliequivalents per liter (meq/L), where 1 meq is equal to 1 mmol of a solute in a solution. In contrast, “osmolality” is the concentration of a solution expressed as the total number of solute particles per kilogram (mOsm/kg).
  • allulose is present in the hydration formulation with a weight of about 0.1 g/L to about 6 g/L, or about 1 g/L to about 6 g/L, 2 g/L to about 6 g/L, or about 2 g/L to about 5 g/L, or about 2 g/L to about 4 g/L, or about 2 g/L to about 3 g/L, or about 3 g/L to about 6 g/L, or about 3 g/L to about 5 g/L, including any amounts or ranges subsumed therein.
  • the hydration formulation includes from 0.75 to 1.5wt% allulose based on the total weight of the hydration formulation, including any amount or ranges subsumed therein.
  • the hydration formulation as described herein is free of any nutritive or artificial sweetener, as defined herein.
  • nutritive and or artificial sweetener is present in the hydration formulation with a weight of about 0.1 g/L to about 2 g/L, or about 0.1 to about 1.5 g/L, or about 0.1 to about 1.25 g/L, or about 0.1 to about 1 g/L, or about 0.1 to about 0.75 g/L, or about 0.1 to about 0.5 g/L, or about 0.1 to about 0.25 g/L, or about 0.5 g/L to about 2 g/L, about 0.5 g/L to about 1.5 g/L, about 0.5 g/L to about 1.25 g/L, about 0.5 g/L to about 1 g/L, about 0.5 g/L to about 0.75 g/L, including any amounts or ranges subsumed therein.
  • the total amount of sodium salt(s) present in the hydration formulation is about 0.1 g/L to about 6.5 g/L, or about 0.1 g/L to about 6.3 g/L, or about 0.1 g/L to about 6 g/L, or about 0.1 g/L to about 5.5 g/L, or about 0.1 g/L to about 5 g/L, or about 0.1 g/L to about 4.5 g/L, or about 0.1 g/L to about 4 g/L, or about 0.1 g/L to about 3.5 g/L, or about 0.3 g/L to about 6.4 g/L, or about 0.3 g/L to about 6 g/L, or about 0.3 g/L to about 5.5 g/L, or about 0.3 g/L to about 5 g/L, or about 0.3 g/L to about 4.5 g/L, or about 0.3 g/L to about 4 g/L, or about about 0.1
  • sodium chloride is present in the hydration formulation is about 0.2 g/L to about 2.2 g/L, or about 0.2 g/L to about 2 g/L, or about 0.2 g/L to about 1.5 g/L or about 0.2 g/L to about 1 g/L, or about 0.2 g/L to about 0.8 g/L, or about 0.3 g/L to about 2 g/L, or about 0.3 g/L to about 1.5 g/L, or about 0.3 g/L to about 1 g/L, or about 0.3 g/L to about 0.8 g/L, or about 0.3 g/L to about 0.7 g/L, including any amounts or ranges subsumed therein.
  • sodium citrates including disodium citrate and/or trisodium citrate, is/are present in the hydration formulation with a weight of about 0.2 g/L to about 2.2 g/L, or about 0.2 g/L to about 2 g/L, about 0.2 g/L to about 1.5 g/L or about 0.2 g/L to about 1 g/L, or about 0.2 g/L to about 0.8 g/L, or about 0.3 g/L to about 2 g/L, or about 0.3 g/L to about 1.5 g/L, or about 0.3 g/L to about 1 g/L, or about 0.3 g/L to about 0.8 g/L, or about 0.3 g/L to about 0.7 g/L, including any amounts or ranges subsumed therein.
  • the total amount of potassium salt(s) present in the hydration formulation is about 0.3 g/L to about 10 g/L, or about 0.3 g/L to about 6 g/L, or about 0.3 g/L to about 5 g/L, or about 0.3 g/L to about 4 g/L, or about 0.3 g/L to about 3 g/L, or about 0.3 g/L to about 2 g/L, or about 0.3 g/L to about 1 g/L, or about 0.6 g/L to about 6 g/L, or about 0.6 g/L to about 5 g/L, or about 0.6 g/L to about 4 g/L, or about 0.6 g/L to about 3 g/L, or about 0.6 g/L to about 2 g/L, or about 0.6 g/L to about 1 g/L, or about 1 g/L to about 6 g/L, or about 1 g/L to about 5 g/L,
  • potassium citrate is present in the hydration formulation with a weight of about 0.2 g/L to about 2 g/L, or about 0.2 g/L to about 1.5 g/L or about 0.2 g/L to about 1 g/L, or about 0.2 g/L to about 0.8 g/L, or about 0.3 g/L to about 2 g/L, or about 0.3 g/L to about 1.5 g/L, or about 0.3 g/L to about 1 g/L, or about 0.3 g/L to about 0.8 g/L, or about 0.3 g/L to about 0.7 g/L, including any amounts or ranges subsumed therein.
  • dipotassium phosphate is present in the hydration formulation with a weight of about 0.2 g/L to about 2 g/L, or about 0.2 g/L to about 1.5 g/L or about 0.2 g/L to about 1 g/L, or about 0.2 g/L to about 0.8 g/L, or about 0.3 g/L to about 2 g/L, or about 0.3 g/L to about 1.5 g/L, or about 0.3 g/L to about 1 g/L, or about 0.3 g/L to about 0.8 g/L, or about 0.3 g/L to about 0.7 g/L, including any amounts or ranges subsumed therein.
  • the total amount of amino acids, as described herein, present in the hydration formulation is about 0.3 g/L to about 4 g/L, or about 0.3 g/L to about 3.5 g/L, or about 0.3 g/L to about 3g/L, or about 0.3 g/L to about 2.5 g/L, or about 0.3 g/L to about 2 g/L, or about 0.3 g/L to about 1.5 g/L, or about 0.3 g/L to about 1 g/L, including any amount or ranges subsumed therein.
  • glutamine or L-glutamine is present in the hydration formulation with a weight of about 0.3 g/L to about 1 g/L, including any amount or ranges subsumed therein.
  • alanine or L-alanine is present in the hydration beverage with a weight of about 0.3 g/L to about 1 g/L, including any amounts or ranges subsumed therein.
  • the total amount of additional agents, as described herein, included in the hydration formulation is about 0.1 g/L to about 9 g/L, or about 0.1 g/L to about 8 g/L, 0.1 g/L to about 7 g/L, 0.1 g/L to about 6 g/L, 0.1 g/L to about 5 g/L, 0.1 g/L to about 4 g/L, 0.1 g/L to about 3 g/L, 0.1 g/L to about 2 g/L, 0.1 g/L to about 1 g/L, or about 0.5 g/L to about 5 g/L, or about 0.5 g/L to about 4 g/L, or about 0.5 g/L to about 3 g/L, or about 0.5 g/L to about 2 g/L, or about 0.5 g/L to about 1 g/L, or about 1 g/L to about 5 g/L, or about 1 g/L to about 5
  • the osmolality of the hydration formulation as described herein is about 210 mOsm/L to about 280 mOsm/L, or about 220 mOsm/L to about 280 mOsm/L, or about 230 mOsm/L to about 280 mOsm/L, or about 240 mOsm/L to about 280 mOsm/L, or about 250 mOsm/L to about 280 mOsm/L, or about 260 mOsm/L to about 280 mOsm/L, 210 mOsm/L to about 270 mOsm/L, or about 215 mOsm/L to about 270 mOsm/L, or about 220 mOsm/L to about 270 mOsm/L, or about 225 mOsm/L to about 270 mOsm/L, or about 230 mOs
  • the osmolality of the hydration formulation as described herein is at least about 210 mOsm/L, or at least about 215 mOsm/L, or at least about 220 mOsm/L, or at least about 225 mOsm/L, or at least about 230 mOsm/L, or at least about 235 mOsm/L, or at least about 240 mOsm/L, or at least about 245 mOsm/L, or at least about 250 mOsm/L, or at least about 255 mOsm/L, but not more than about 260 mOsm/L.
  • the hydration formulation as described herein includes (a) allulose in an amount of about 0.1 to about 6 g/L, or about 1 g/L to about 6 g/L, or about 3 g/L to about 6 g/L; (b) one or more sodium salts, in an amount of about 1 to about 5 g/L, or about 1 g/L to about 3 g/L, or about 0.3 g/L to about 1.5 g/L; and (c) one or more potassium salts, in an amount of about 0.3 g/L to about 6 g/L, or about 0.3 g/L to about 3 g/L, or about 0.6 g/L to about 6 g/L or about 0.6 g/L to about 3 g/L.
  • the hydration composition has at least one citrate salt selected from sodium citrates, potassium citrate, zinc citrate, and/or any combinations or mixtures thereof.
  • at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • a g/L to about 2 g/L there is about 0.1 g/L to about 2 g/L, or about 0.1 g/L to about 1.5 g/L, or about 0.2 g/L to about 1 g/L, or about 0.1 g/L to about 0.5 g/L of nutritive or artificial sweetener, wherein nutritive or artificial sweetener is stevia.
  • the hydration formulation may optionally include about 0.1 g/L to about 9 g/L, or about 0.1 to about 5 g/L, or about 0.1 g/L to about 3 g/L of additional agents, as described herein.
  • the hydration formulation as described herein includes (a) allulose in an amount of about 0.1 to about 6 g/L, or about 1 g/L to about 6 g/L, or about 3 g/L to about 6 g/L; (b) sodium salt, wherein the sodium salt is sodium chloride, sodium citrate or a mixture thereof in an amount of about 1 to about 5 g/L, or about 1 g/L to about 3 g/L, or about 0.3 g/L to about 1.5 g/L; (c) potassium salt, wherein the potassium salt is potassium citrate, dipotassium phosphate or mixtures thereof in an amount of about 0.3 g/L to about 6 g/L, or about 0.3 g/L to about 3 g/L, or about 0.6 g/L to about 6 g/L, or about 0.6 g/L to about 3 g/L.
  • a g/L to about 2 g/L there is about 0.1 g/L to about 2 g/L, or about 0.1 g/L to about 1.5 g/L, or about 0.2 g/L to about 1 g/L, or about 0.1 g/L to about 0.5 g/L of nutritive or artificial sweetener, wherein nutritive or artificial sweetener is stevia.
  • the hydration formulation may optionally include about 0.1 g/L to about 9 g/L, or about 0.1 to about 5 g/L, or about 0.1 g/L to about 3 g/L of additional agents, as described herein.
  • the hydration formulation as described herein includes (a) allulose in an amount of about 0.1 to about 6 g/L, or about 1 g/L to about 6 g/L, or about 3 g/L to about 6 g/L; (b) sodium salt, wherein the sodium salt is sodium chloride, sodium citrate or a mixture thereof in an amount of about 1 to about 5 g/L, or about 1 g/L to about 3 g/L, or about 0.3 g/L to about 1.5 g/L; (c) potassium salt, wherein the potassium salt is potassium citrate, dipotassium phosphate or mixtures thereof in an amount of about 0.3 g/L to about 6 g/L, or about 0.3 g/L to about 3 g/L, or about 0.6 g/L to about 6 g/L, or about 0.6 g/L to about 3 g/L.
  • the hydration composition comprises at least one amino acid, preferably selected from glutamine, L-glutamine, alanine, L-alanine and/or combinations thereof, and when present, the total amount of amino acids included in the hydration composition is about 0.6 to about 2 g/L.
  • the hydration formulation may optionally include about 0.1 g/L to about 9 g/L, or about 0.1 to about 5 g/L, or about 0.1 g/L to about 3 g/L of additional agents, as described herein.
  • the hydration formulation as described herein includes (a) a core base comprising allulose and sodium chloride, and (b) an electrolyte base comprising one or more potassium salts, and optionally, one or more sodium salts other than sodium chloride.
  • at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • the core base is about 3 to about 7 g/L
  • the electrolyte base is about 0.2 to about 2 g/L.
  • a processing aid there is about 0.1 g/L to about 9 g/L, or about 0.1 to about 5 g/L, or about 0.1 g/L to about 3 g/L of additional agents, as described herein.
  • the hydration formulation as described herein includes a (a) core base comprising allulose, sodium chloride and at least one amino acid, and (b) an electrolyte base comprising one or more potassium salts, and optionally, one or more sodium salts other than sodium chloride.
  • at least one of the one or more sodium salts and/or one or more of the potassium salts is a citrate salt, preferably sodium citrate, disodium citrate, trisodium citrate, potassium citrate and/or mixtures or combinations thereof.
  • the at least one amino acid is L-alanine and/or L-glutamine.
  • the core base is about 3 to about 6 g/L
  • the electrolyte base is about 0.1 to about 1 g/L.
  • the hydration formulation may optionally include about 0.1 g/L to about 9 g/L, or about 0.1 to about 5 g/L, or about 0.1 g/L to about 3 g/L of additional agents, as described herein.
  • the hydration formulation as described herein has a beverage hydration index (BHI) of greater than 1.
  • BHI beverage hydration index
  • the hydration formulation as described herein has a BHI of 1.1 to 2.0, or 1.1 to 1.6, or 1.1 to 1.5, or 1.1 to 1.4, or 1.2 to 2.0, or 1.2 to 1.6, or 1.2 to 1.5, or 1.2 to 1.4, or 1.2 to 1.3, or 1.3 to 2.0, or 1.3 to 1.6, or 1.3 to 1.5, or 1.4 to 2.0, or 1.4 to 1.6, or 1.4 to 1.5, or 1.5 to 2.0, or 1.5 to 1.6, including any ranges subsumed therein.
  • BHI is a composite measure of fluid balance after consuming a beverage relative to water, and may be calculated as the ratio of cumulative urine mass for distilled water divided by the cumulative urine mass of the test beverage at certain time points (see, e.g., Maughan et aL, “A randomized trial to assess the potential of different beverages to affect hydration status: Development of a beverage hydration index”, The American Journal of Clinical Nutrition, 103(3), 717-723 (2016)).
  • a BHI over 1 means more water is retained in the body than if the drinker had consumed an equal volume of still water.
  • Plasma osmolality is a test that assesses electrolyte-water balances. It measures the concentration of dissolved particles, e.g., osmolality, in blood. This test has been used to help diagnose fluid or electrolyte imbalances and dehydration (Nose et al., “Role of osmolality and plasma volume during rehydration in humans”, Journal of Applied Physiology, 65(1), pp. 325-331 (1988)). Lower plasma osmolality values suggest higher levels of hydration.
  • plasma osmolality may be tested using a single sample osmometer.
  • the instrument should be calibrated prior to measurements using a set of standard linearity controls encompassing a range of 100-2,000 mOsm/kg. Measurements can be taken in a repeating pattern. Blood samples may be obtained from an indwelling catheter in a vacutainer, or from finger stick if blood cannot be obtained from the catheter.
  • blood samples for the assessment of plasma osmolality can be collected prior to a set time of activity such as running, jogging, walking, cycling, swimming, rowing, weight training, yoga, or other forms of exercise or physical activity (e.g., about 1 to about 120 minutes, or about 30 to about 100 minutes, or about 50 to about 80 minutes), as well as for a period post-activity, such as at 0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, and/or 120, preferably where the post-activity period is in the absence of the activity (e.g., resting, or seated rest).
  • a set time of activity such as running, jogging, walking, cycling, swimming, rowing, weight training, yoga, or other forms of exercise or physical activity (e.g., about 1 to about 120 minutes, or about 30 to about 100 minutes, or about 50 to about 80 minutes), as well as for a period post-activity, such as at 0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, and/or 120, preferably where the
  • administration of the hydration composition and/or formulation as described herein, during or after an activity may decrease plasma osmolality following the administration of the hydration composition and/or formulation by about 2% to about 9%, or about 3% to about 9%, or about 3% to about 7%, or about 3% to about 6%, or about 3% to about 5%, or about 4% to about 9%, or about 4% to about 8%, about 4% to about 7%, or about 4% to about 6%, about 4% to about 5%, or about 5% to about 9%, or about 5% to about 8%, or about 5% to about 7%, or about 6% to about 9%, or about 6% to about 8%.
  • Blood plasma is a liquid component of blood that contains proteins and other ingredients of whole blood but lacks blood cells. It accounts for approximately 55% of the total blood volume in the body. It is mostly water (up to 95% by volume) and contains dissolved proteins, glucose, clotting factors, electrolytes, hormones, carbon dioxide, oxygen, and excretory products. It is essential in an intravascular osmotic effect that maintains electrolyte balance.
  • a high plasma volume can improve performance by increasing stroke volume and maximal cardiac output, as well as improving muscle perfusion. Plasma volume expansion improves thermoregulatory responses to exercise by boosting cutaneous blood flow. Higher plasma volumes suggest higher levels of hydration (see, e.g., N. Fellmann, “Hormonal and plasma volume alterations following endurance exercise. A brief review”, Sports Med, 13(1), pp. 37-49 (1992)).
  • blood samples for the assessment of plasma volume can be collected prior to a set time of activity such as running, jogging, walking, cycling, swimming, rowing, weight training, yoga, or other forms of exercise or physical activity (e.g., about 1 to about 120 minutes, or about 30 to about 100 minutes, or about 50 to about 80 minutes), as well as for a period post-activity, such as at 0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, and/or 120, preferably where the post-activity period is in the absence of the activity (e.g., resting, or seated rest).
  • a set time of activity such as running, jogging, walking, cycling, swimming, rowing, weight training, yoga, or other forms of exercise or physical activity (e.g., about 1 to about 120 minutes, or about 30 to about 100 minutes, or about 50 to about 80 minutes), as well as for a period post-activity, such as at 0 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, and/or 120, preferably where the post-activity period
  • administration of the hydration composition and/or formulation as described herein, before, during or after an activity may increase plasma volume following the administration of the hydration composition and/or formulation by about 2% to about 12%, or about 3% to about 12%, or about 3% to about 10%, or about 3% to about 8%, or about 3% to about 7%, or about 3% to about 6%, or about 4% to about 12%, or about 4% to about 10%, about 4% to about 8%, or about 4% to about 7%, about 4% to about 6%, or about 5% to about 12%, or about 5% to about 10%, or about 5% to about 8%, or about 6% to about 12%, or about 6% to about 10%, or about 6% to about 8%.
  • volitional exhaustion is a subject’s inability to continue a physical activity (e.g., exercise) despite any external encouragement to continue said physical activity.
  • the hydration composition may be used in an edible product.
  • An edible product as defined herein, is suitable for being eaten or otherwise consumed such as gummies or frozen treats including popsicles, slush, shaved ice, sorbets, ice creams.
  • a method for making the hydration composition as disclosed herein is provided in a blender for about 1 minutes to about 60 minutes, or about 5 minutes to about 30 minutes, wherein the first batch comprises the allulose, one or more sodium salt, and one or more potassium salts, and optionally an acidifier and/or an amino acid;
  • a second batch is prepared wherein the second batch comprises a processing aid, and, optionally, a nutritive or artificial sweetener and/or at least one additional agent, preferably one or more vitamins and/or minerals; and the first and the second batches are combined and mixed for about 1 minute to about 60 minutes, or about 5 minutes to about 30 minutes, depending on the batch size.
  • a method for making the hydration composition as disclosed herein is combined and mixed in a ribbon blender for about 1 minutes to about 60 minutes, or about 5 minutes to about 30 minutes, wherein the first batch comprises the allulose, one or more sodium salt(s), preferably sodium chloride and at least one additional sodium salt other than sodium chloride such as sodium citrate, and one or more potassium salt(s), preferably potassium citrate and/or dipotassium phosphate.
  • This first batch may also include, an acidifier such as citric acid, and optionally, at least one amino acid, where the amino acid may be L-alanine and/or L-glutamine.
  • a portion of the first batch preferably, about half by weight, is retained in the ribbon blender.
  • a second batch is prepared a processing aid, and, optionally, a nutritive or artificial sweetener and/or at least one additional agent such as vitamin(s) and/or mineral.
  • the second batch is then added along the center axle of the ribbon blender.
  • the remaining portion of the first batch is added to the ribbon blender which is mixed for about 1 minute to about 60 minutes, or about 5 minutes to about 30 minutes, depending on the batch size.
  • a subject in need thereof is preferably a human, who may be in need of hydration.
  • the rehydration formulation is prepared by diluting and dissolving a rehydration composition as described herein, in a beverage product so that it is dissolved, and the hydration formula has an osmolarity as described herein.
  • the hydration formulation is then consumed or ingested by the subject in need thereof.
  • the hydration composition as described herein is made by combining allulose, citric acid, flavorings, sodium citrate, potassium citrate, dipotassium phosphate sodium chloride, and optionally, amino acids (e.g., L-glutamine and/or L-alanine) in a first batch.
  • the first batch is mixed in a ribbon blender for a predetermined mixing time (about 5-30 minutes) depending on the batch size, rotations per minute and design of the blending system.
  • a portion of first batch (preferably, about half by weight) is retained in the ribbon blender.
  • a second batch is made which includes a combination of the vitamins, silicon dioxide and stevia. This batch is then added along the center axle of the ribbon blender. Then, the remaining portion of the first batch is added back to the ribbon blender followed by mixing for 5-30 minutes depending on the batch size, rotations per minute and design of the blending system.
  • compositions in the Table below were prepared in accordance with the method set forth in Example 1 hereinabove.
  • Hydration Composition A is dissolved in about 0.473 L of water.
  • the osmolarity of hydration formulation 1 is about 240 to about 255mmol/L.
  • Hydration Composition B is dissolved in about 0.473 L of water.
  • the osmolarity of hydration formulation 2 is about 240 to about 255mmol/L.
  • Caco-2 cells originated from a well-differentiated human colon adenocarcinoma, is an in vitro epithelial model widely used to study intestinal absorption.
  • the epithelial monolayer exhibits the characteristic functions of small intestinal enterocytes, including organization of the apical brush border, high expression of key transporters (e.g., P-gp and BCRP) and intercellular tight junctions (e.g., ZO-1 and occludin).
  • key transporters e.g., P-gp and BCRP
  • intercellular tight junctions e.g., ZO-1 and occludin
  • Caco-2 I TC7 comprises a homogeneous population of epithelial cells derived from the classical Caco-2 cells.
  • the cells are seeded in polycarbonate filters, which allows them to attach and differentiate to form a tight epithelial monolayer similar to the intestinal barrier.
  • the cells are cultivated for 21 days to reach confluence and maturate, being ready for use from 21 until 31 days after seeding.
  • the test system used in the study is validated by measuring the transepithelial electrical resistance (TEER); only Caco-2/TC7 monolayers that meet the acceptance criteria (TEER > 500 ohms) were used for the study.
  • a Cell incubator was used thermostated at 37 ⁇ 2 °C and 10 ⁇ 1 % CO2.
  • the Plate reader used was from BMG Labtech.
  • a World Precision Instruments Evometer (EVOM2) was used to measure TEER (transepithelial electrical resistance).
  • Calculation software employed was Microsoft Excel 2003, 2007, 2010, 2016 and for Microsoft 365
  • the Nanodrop spectrophotomer and QuantStudioTM 5 Flex Real-Time were obtained from Thermo-Fisher.
  • HM was a hydration formula including glucose
  • SF composition indicated above
  • the water absorption was determined by measuring the volume of liquid (medium) in the apical compartment. An initial volume of 200 pl was added to the apical compartment and changes (gain or loss of volume) to the volume were monitored. Loss of volume means that there is absorption of liquid from apical (top) to basolateral (lower) compartment, while gain of volume means that there is passage of liquid from basolateral to apical compartment.
  • the apical compartment represents the lumen of the intestines while the basolateral compartment represents the membrane between the intestine and the bloodstream.
  • Control vehicle - medium: medium (Assay medium) that was used to solubilize the test items.
  • the medium is Dulbecco’s Modified Eagle’s Medium - High Glucose supplemented with penicillin, streptomycin, newborn calf serum and MEM non essential amino acid solution.
  • Mannitol (2.5%), an osmotic diuretic that elevates osmolality, facilitating the absorption of water. Mannitol was used in the basolateral compartment to mimic the osmolarity of the human body wherein osmolarity is typically lower in the lumen of the digestive system than on the other side of the epithelium (represented in this experiment by the basolateral compartment).
  • HM containing glucose
  • SF containing allulose and limited amounts of stevia but otherwise no nutritive, non-nutritive or artificial sweeteners at [C1 ]
  • Study A The treatment was performed in order to check a potential effect of the rehydration beverage containing allulose and limited amounts of stevia but otherwise no nutritive, non-nutritive or artificial sweeteners on liquid absorption across Caco-2/TC7 cells.
  • Cells were treated during 24 hours with the test items in the apical compartment, while normal medium was added in the lower compartment.
  • Control cells received normal medium in both compartments, while the positive control consisted of adding Mannitol 2.5% in the lower compartment to induce water absorption mediated by osmolarity gradient.
  • the volume of medium in the upper compartment and the TEER were measured after 1 , 3, 6 and 24 hours of treatment.
  • the cells of this study which did not include mannitol were intended to show that the experimental setup works rather than to mimic osmolarity gradients in humans, as is done in later experiments. The results can be seen in Fig. 1.
  • Schedule 1 This treatment schedule was performed in order to check the acute effect of test items in presence of an osmolarity gradient between the apical and basolateral compartment. This approach was tested in order to balance the osmotic gradient between the treatments. Cells were treated during 24 hours with the test items in the apical compartment. Mannitol 2.5% was added in all conditions but the control (just medium in both sides) to equilibrate the osmolarity and facilitate the water absorption. For this experiment, the volume of medium in the upper compartment was measured at
  • TEER was also measured at 6 and 24 hours. Results are shown in Fig. 3. At the end, a MTT assay (assay for cellular metabolic activity) and paracellular permeability assessment were performed to assess the cell viability and barrier integrity. Results for 24 hours are shown in Fig. 4.
  • Schedule 2 This treatment schedule was performed in order to check the middle/long- effect of test items, as well as to investigate a potential biological effect on Caco-2/TC7 cells (e.g. regulation of transporter activity) that are independent of osmolarity gradient.
  • Cells were treated during 24 or 48 hours with test items in the apical compartment, while normal medium was added in the lower compartment. Mannitol 2.5% was added in the lower compartment of the Positive Control group, and it was used as an inducer of water absorption mediated by osmolarity gradient.
  • the volume of medium in the upper compartment and the TEER were measured at 24 hours (for 24 h treatment) or 48 hours (for 48 h treatment).
  • the TEER was measured by using an Evometer (EV0M2) to assess the transcellular permeability of the intestinal barrier.
  • Evometer Evometer
  • cells were rinsed with PBS and submitted to an assay to determine the paracellular permeability.
  • LY 200 pM
  • filters were placed in 24- well plates containing 600 pl of fresh Assay medium. After one hour of incubation (37 ° C, CO2 incubator), the fluorescence emitted by LY was measured in both apical and basolateral compartments.
  • the Caco-2/TC7 monolayers were dried with paper towels, and then transferred to another 24-wells plate containing 300 pl/well of MTT dye solution (1 mg/ml MTT in the medium), and the plates were incubated in the dark for 1 hour ⁇ 5 minutes (37 ⁇ 1 °C, 5 ⁇ 1 % CO2).
  • the Caco-2/TC7 monolayers were dried with paper towels and transferred into a 24-wells plate containing 1 ml of isopropanol, then 1 ml of isopropanol were added to the top of each insert. The plates were incubated for at least 30 minutes at room temperature.
  • Figure 1 represents the first experiments with the test item SF (rehydration beverage containing allulose and small amounts of stevia but otherwise no nutritive, non-nutritive or artificial sweeteners) and the positive control (mannitol). Such experiments were performed in order to investigate the effects of the SF beverage on liquid absorption across the Caco-2/TC7 model, as well as to optimize the best conditions (e.g. time of exposure) for evaluating the liquid absorption.
  • SF rehydration beverage containing allulose and small amounts of stevia but otherwise no nutritive, non-nutritive or artificial sweeteners
  • the positive control mannitol
  • mannitol As expected, the presence of mannitol (2.5%) in the lower compartment induced liquid absorption from luminal to basolateral compartment. This effect is possibly mediated by the osmolarity gradient created by mannitol, as may be expected in human systems where a gradient typically exists of lower osmolarity in the lumen to higher osmolarity in the blood. The mannitol-induced water absorption was followed by a marked decrease on TEER at the first time points (1 , 3, and 6 hours), however it recovered at 24 hours. As for mannitol, this effect was possibly mediated by the osmolarity gradient created by adding the test item. In the absence of an osmolarity gradient created by mannitol in the basolateral compartment, fluid flowed from the basolateral compartment to the luminal (apical) compartment.
  • Figure 2 shows the calculated osmolarity at the luminal and basolateral compartments, according to the described treatments.
  • Adding mannitol in the lower, basolateral, compartment of treated cells wherein the test solution is allulose-containing hydration formula with limited amounts of stevia and otherwise free of nutritive, non-nutritive and artificial sweeteners decreased the difference of osmolarity between the luminal and basolateral compartment, allowing then to observe a positive effect of the test item on liquid absorption.
  • isotonic conditions Control and highest concentration of test items [C3]
  • a small volume of liquid crosses the Caco-2/TC7 cells, without marked effect on TEER.
  • test solution induced higher liquid absorption at 6 and 24 hours without any effect on TEER, suggesting it might be mediated by other factors (e.g. active transport) without osmotic gradient.
  • test solution rehydration beverage containing allulose and a small amount of stevia, but otherwise no nutritive, non-nutritive or artificial sweeteners
  • Mannitol Figure 3
  • the intestine contains a simple layer of epithelial cells that plays a key role in the uptake of nutrients, reabsorption of water, and the prevention of pathogen invasion.
  • the transport of substances across the epithelial intestine occurs through the transcellular and paracel I ular pathway.
  • the substances should be taken up by the epithelial cells by pinocytosis or by action of transporters.
  • the main mechanisms include the passive diffusion across the cell membrane or the carrier- mediated pathway (carrier/receptor-mediated transcellular pathway).
  • carriers/receptor-mediated transcellular pathway for the paracellular pathway, substances should be transported through the lateral borders of the cells.
  • Caco-2 cells grown on permeable support have been widely used as a tool to study the in vitro absorption of substances in the intestine, since it expresses the main transporters present on intestinal epithelium and presents a well- organized tight junction and adherens junctions at the cell borders. For this reason, the Caco-2 model was chosen to study the effect of the hydration formulation with no nutritive, non-nutritive, or artificial sweeteners on water absorption.
  • the addition of the hydration formulation with no nutritive, non- nutritive- or artificial-sweeteners test item to the luminal compartment promotes an osmotic gradient of around 130 mosmol/L (for the highest concentration) between the luminal and the basolateral compartments, leading to a dose-dependent movement of water from basolateral to luminal compartment.
  • the present study has confirmed that the Caco-2/TC7 is suitable for studying water absorption in vitro.
  • the allulose containing hydration formula without nutritive sugar non-nutritive sugar or artificial sweetener (SF) had no toxic effects, even at the highest concentrations employed in this study.
  • Other promising findings include the water absorption against the osmotic gradient induced by the (SF) at the highest concentration and the effect on barrier tightness.
  • SF was shown to promote intestinal water absorption.
  • Concentrations of allulose in the hydration formula (based on the total weight of the hydration formula) at which transport across the epithelium may be expected include 5mg/mL - 50 mg/mL, especially 5mg/mL - 40 mg/mL.
  • Caco-2 1 TC7 comprises a similar population of intestinal cells derived from the classical Caco-2 cells. The cells are cultivated for 21 days to reach confluence and maturate, being then ready for use.
  • the test system used in the study is the transepithelial electrical resistance (TEER).
  • the water absorption is determined by measuring the volume of liquid in the apical compartment. An initial volume of 200 pl is added in the apical compartment and changes (gain or loss of volume) on the volume were monitored. Loss of volume means that there is absorption of liquid from apical (top) to basolateral (lower) compartment, while gain of volume means that there is passage of liquid from basolateral to the apical compartment.
  • Control vehicle - medium: medium (Assay medium) that is used to solubilize the test items.
  • Schedule 1 This treatment schedule is performed in order to check the acute effect of test items in presence of an osmolarity gradient between the apical and basolateral compartment. This approach is tested in order to balance the osmotic gradient between the treatments.
  • Cells are treated during 24 hours with the test items in the apical compartment. Mannitol 2.5% is added in all conditions but the control to equilibrate the osmolarity and facilitate the water absorption.
  • the volume of medium in the upper compartment is measured at 6 and 24 hours.
  • TEER is also measured at 6 and 24 hours.
  • a MTT assay and paracellular permeability assessment are performed to assess the cell viability and barrier integrity.
  • Schedule 2 This treatment schedule is performed in order to check the middle/long- effect of test items, as well as to investigate a potential biological effect on Caco-2/TC7 cells that are independent of osmolarity gradient.
  • Cells are treated during 24 or 48 hours with test items in the apical compartment, while normal medium is added in the lower compartment. Mannitol 2.5% is added in the lower compartment of the Positive Control group, and it is used as an inducer of water absorption mediated by osmolarity gradient.
  • the volume of medium in the upper compartment and the TEER are measured at 24 hours or 48 hours.
  • Cells are rinsed and mannitol 2.5% is added on basolateral compartment for all conditions, to stimulate the water passage from luminal to abluminal compartment. After 6 hours, the volume of medium in the apical compartment is measured, in parallel to the measure of TEER.
  • a MTT assay and paracellular permeability assessment is performed to assess the cell viability and barrier integrity.
  • the TEER is measured by using an Evometer to assess the transcellular permeability of the intestinal barrier.
  • cells are rinsed with PBS and submitted to an assay to determine the paracellular permeability.
  • LY a marker of paracellular permeability presenting low passage across the intestinal barrier, is added to the apical compartment. Then, filters are placed in 24-well plates containing fresh Assay medium. After one hour of incubation, the fluorescence emitted by LY is measured in both apical and basolateral compartments.
  • cells are rinsed with PBS and the cell viability is determined by the MTT assay.
  • the Caco-2/TC7 monolayers are dried with paper towels, and then transferred to another 24-wells plate containing MTT dye solution, and the plates are incubated in the dark for 1 hour ⁇ 5 minutes.
  • the Caco-2/TC7 monolayers are dried with paper towels and transferred into a 24-wells plate containing isopropanol, then isopropanol is added to the top of each insert. The plates are incubated for at least 30 minutes at room temperature. Finally, the inserts are pierced to ensure the mixture recovery of the supernatant and the subnatant isopropanol. Isopropanol extracts are briefly homogenized, transferred onto a 96 wells plate and the optical density (OD) is measured in duplicate. At 6 hours intestinal absorption in the range of 5 through 40 mL and 0.8 through 6.7 mL per hour are obtained.
  • intestinal absorption in the range of 10-60 mL or 0.4 through 2.5 mL per hour are obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition d'hydratation comprenant : de l'allulose ; un ou plusieurs sels de sodium ; et un ou plusieurs sels de potassium ; la composition contenant moins d'environ 10 %, de préférence moins d'environ 5 %, de préférence encore moins d'environ 3 %, et idéalement moins d'environ 1 %, ou 0 %, en poids, d'un édulcorant nutritif ou artificiel ; et, éventuellement, au moins un sel parmi le ou les sels de sodium et/ou le ou les sels de potassium étant un sel de citrate, de préférence du citrate de sodium, du citrate disodique, du citrate trisodique, du citrate de potassium et/ou des mélanges ou des combinaisons de ceux-ci.
PCT/EP2023/072316 2022-08-11 2023-08-11 Composition d'hydratation WO2024033533A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263397302P 2022-08-11 2022-08-11
US63/397,302 2022-08-11
EP22193060 2022-08-31
EP22193060.5 2022-08-31

Publications (1)

Publication Number Publication Date
WO2024033533A1 true WO2024033533A1 (fr) 2024-02-15

Family

ID=87571797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/072316 WO2024033533A1 (fr) 2022-08-11 2023-08-11 Composition d'hydratation

Country Status (1)

Country Link
WO (1) WO2024033533A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5314207B1 (ja) * 2013-03-14 2013-10-16 株式会社 伊藤園 ミネラル含有飲料及びその製造方法、並びにミネラル含有飲料の塩味抑制方法
US20190059434A1 (en) * 2014-11-19 2019-02-28 Kalmarna Limited Oral rehydration composition and methods thereof
EP2993990B1 (fr) * 2013-03-14 2019-11-13 The Coca-Cola Company Boissons contenant des sucres rares

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5314207B1 (ja) * 2013-03-14 2013-10-16 株式会社 伊藤園 ミネラル含有飲料及びその製造方法、並びにミネラル含有飲料の塩味抑制方法
EP2993990B1 (fr) * 2013-03-14 2019-11-13 The Coca-Cola Company Boissons contenant des sucres rares
US20190059434A1 (en) * 2014-11-19 2019-02-28 Kalmarna Limited Oral rehydration composition and methods thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"New formula oral hydration salts", WHO DRUG INFORMATION, vol. 16, no. 2, 2002, Retrieved from the Internet <URL:apps.who.int/medicinedocs/en/d/Js4950e/2.4.html>
MAUGHAN ET AL.: "A randomized trial to assess the potential of different beverages to affect hydration status: Development of a beverage hydration index", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 103, no. 3, 2016, pages 717 - 723
N. FELLMANN: "Hormonal and plasma volume alterations following endurance exercise. A brief review", SPORTS MED, vol. 13, no. 1, 1992, pages 37 - 49
NOSE ET AL.: "Role of osmolality and plasma volume during rehydration in humans", JOURNAL OF APPLIED PHYSIOLOGY, vol. 65, no. 1, 1988, pages 325 - 331
ORAL HYDRATION SALTS (ORS) A NEW REDUCED OSMOLARITY FORMULATION, 10 May 2002 (2002-05-10), Retrieved from the Internet <URL:rehydrate.org/ors/who-unicef-statement.html>

Similar Documents

Publication Publication Date Title
US6051236A (en) Composition for optimizing muscle performance during exercise
US6713082B2 (en) Composition comprising carbohydrate and peptide material and its use as an energy supplement after or during physical exercise or as a metabolic nutrient for oral consumption
US9757345B2 (en) Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
US20200281968A1 (en) Physical optimization beverage
US7375089B2 (en) Rehydration composition
CN108778269A (zh) 包含烟碱酰胺核糖苷和尿石素的组合物
CN101248873A (zh) 具有视力保护功能的饮用食品
CN104853621A (zh) 使用人乳寡糖用于调节炎症的营养制剂
US9872871B2 (en) Compositions for use in restoring muscle glycogen and/or muscle mass
CN104159592A (zh) 酪蛋白组合物的用途
US20200077682A1 (en) Beverage with collagen and additional additives
US20030104107A1 (en) Energy drink formula and method
Stadler et al. Effect of dietary macronutrient content on carnitine excretion and efficiency of carnitine reabsorption
CN101263840B (zh) 一种含有核糖的奶粉及其制备方法
EP2627196B1 (fr) Smoothie à base de produits laitiers pour stimuler la croissance chez des enfants
WO2024033533A1 (fr) Composition d&#39;hydratation
US20200054045A1 (en) All-Natural Drink Composition for Synthesizing and Regenerating Adenosine Triphosphate (ATP) in Muscle Cells and Neurons, Repairing Exercise-Induced Muscle Fiber Damage, Repletion of Glycogen Stores in the Muscle and Liver, Enhancing Blood Flow to Tissue during Intense Exercise, and Preventing and Reducing Oxidative Damage to Tissues during Exercise with Minimal Gastrointestinal Disturbances
AU2004241884A2 (en) A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein
KR20140129439A (ko) 운동 후 근육 피로 개선용 식품 조성물
JP2020519698A (ja) サプリメントの吸収向上のための組成物
CZ32011U1 (cs) Nutriční kompozice
KR20120119686A (ko) Ｌ-아르기닌, 비타민ｃ, 비타민 ｂ군, 비타민ａ, 비타민ｅ 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물
JP2018519355A (ja) 透析後ウォッシュアウトを改善する方法およびこのような方法において使用するための栄養補助食品
Sapa et al. Effects of Exercise on Glycemic Response after Consumption of Monster Energy
JP2023501625A (ja) コラーゲンおよび追加の添加剤入り飲料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23754802

Country of ref document: EP

Kind code of ref document: A1